# Cobenfy (trospium chloride; xanomeline tartrate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/trospium-xanomeline

> The FDA approved Cobenfy (trospium chloride; xanomeline tartrate), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on September 26, 2024 for to treat schizophreniaPress Release.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Cobenfy (trospium chloride; xanomeline tartrate) FDA approved?

Yes. The FDA approved Cobenfy (trospium chloride; xanomeline tartrate), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on September 26, 2024 for to treat schizophreniaPress Release. FDA novel drug approvals: "Cobenfy | xanomeline and trospium chloride | 9/26/2024 | To treat schizophreniaPress ReleaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/trospium-xanomeline)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/trospium-xanomeline#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cobenfy (trospium chloride; xanomeline tartrate) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | To treat schizophreniaPress Release |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat schizophreniaPress Release.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Cobenfy | xanomeline and trospium chloride | 9/26/2024 | To treat schizophreniaPress ReleaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA216158 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240926, review_priority STANDARD; sponsor_name BRISTOL-MYERS; product COBENFY (TROSPIUM CHLORIDE; XANOMELINE TARTRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216158%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/trospium-xanomeline.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cobenfy (trospium chloride; xanomeline tartrate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/trospium-xanomeline

```bibtex
@misc{secapidev_pdufa_trospium_xanomeline_20261116,
  title        = {Cobenfy (trospium chloride; xanomeline tartrate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/trospium-xanomeline}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_trospium_xanomeline_20261116","title":"Cobenfy (trospium chloride; xanomeline tartrate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/trospium-xanomeline","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
